Is MDXG or STLN more profitable?

MDXG runs the higher net margin — MDXG at 1.76% versus STLN at -6.18%.

MiMedx Group, Inc. (MDXG) vs Starling Oncology, Inc. (STLN)

A side-by-side comparison of MiMedx Group, Inc. and Starling Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

MDXG

MiMedx Group, Inc.

$673M

$4.62HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

STLN

Starling Oncology, Inc.

$658M

$6.58HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MDXG vs STLN

growth of $100 · dividends reinvested · last 1y

MDXG +15.2% (+15.2%/yr)STLN +8.6% (+8.6%/yr)MDXG compounded faster over this window

MDXG STLN

MDXG vs STLN: by the numbers

•MDXG is the larger company ($673M vs $658M market cap).
•MDXG is profitable (1.76% net margin) while STLN runs a net loss (-6.18%).

Metrics side by side

Valuation

Metric	MDXG	STLN
P/E ratio	115.50	N/A
P/S ratio	1.90	1.12
P/B ratio	3.12	N/A
EV / EBITDA	26.41	N/A
FCF yield	6.03%	N/A

Profitability

Metric	MDXG	STLN
Gross margin	78.85%	15.69%
Operating margin	15.26%	-4.44%
Net margin	1.76%	-6.18%
ROE	2.89%	N/A
ROIC	1.97%	-31.32%

Growth (annualized)

Metric	MDXG	STLN
Revenue CAGR (5Y)	6.36%	N/A
Total return CAGR (5Y)	-4.94%	N/A

Frequently asked

Is MDXG or STLN more profitable?: MDXG runs the higher net margin — MDXG at 1.76% versus STLN at -6.18%.

Go deeper

Full MDXG analysis Full STLN analysis Interactive comparison tool

Dig into the metrics

MiMedx P/E ratio MiMedx ROE Starling Oncology ROE MiMedx operating margin Starling Oncology operating margin MiMedx revenue growth Starling Oncology revenue growth MiMedx free cash flow Starling Oncology free cash flow

MiMedx & Starling Oncology appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.